Abionic’s cSOFA score assesses the severity of Covid-19 among patients within only five minutes of analysing a blood sample. With the launch of the CE-Mark certified device, the company aims to prevent hospital overload by allowing health workers to assign patients to general wards, intensive care units or discharge them from the hospital.
Since the outbreak of the Covid-19 pandemic, countries around the globe have seen increasing occupancy rates in hospitals, particularly in ICUs, and many ICUs are at or near full capacity. Patient triage, until now, has relied mostly on patient age, a criterion sometimes criticized for being discriminatory. The Swiss startup Abionic has launched the cSOFA score (Covid Sequential Organ Failure Assessment) enables a shift from demographic to medical criteria, taking into account the severity of each case.
The cSOFA score measures the likelihood of clinical deterioration in Covid-19 patients before the presence of clear clinical signs. A mere 50 ul drop of capillary blood is required upon arrival and can be taken upon arrival by a receptionist, without the need of medical training. Within only five minutes, the tool will deliver the results that serve as a base for assigning Covid-19 patients. A low score allows for making faster medical decisions on safely discharging patients from the hospital or moving them from the ICU to the general ward, thus freeing up much-needed ICU and hospital capacities.
The newly launched cSOFA relies on PSP (pancreatic stone protein), a novel biomarker Abionic has already clinically validated and marketed. PSP is characterised by its diagnostic accuracy in predicting sepsis and/or multiple organ dysfunction in various types of critically ill patients. Data from 150+ Covid-19 patients from the first European wave of SARS-CoV-2 infections shows a strong link between PSP concentration and the degradation of these patients. The tool has already obtained the authorisation to sell in Europe (CE mark).
Multiple application device
cSOFA score is a further development from the already widespread SOFA score (Sequential Organ Failure Assessment), used to track a person's status during a stay in an intensive care unit (ICU). Csofa is much faster and is applicable to a wide range of fields. “Our research also indicates that modifications to the cSOFA score may be used as severity measures for other illnesses, such as flu, sepsis and other inflammatory disorders,” said Nicolas Durand, CEO of Abionic.
Abionic is a Swiss Medtech company commercializing a revolutionary nanofluidic technology, providing healthcare professionals with a fast, simple and universal diagnostic tool. Abionic’s cutting-edge Nanotechnology enhances efficiency and versatility of standard ELISA tests to deliver optimal point of care (POC) treatment options with the ability to reduce the current biological techniques from macroscale to nanoscale in a multi-analyte environment. Abionic’s In Vitro Diagnostic (IVD) platform provides lab-quality results in 5 minutes from a single drop of blood at the POC enabling personalized diagnostics and the possibility of immediate treatment initiation.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines